flects the pathology of thrombocytopenic disorders and the measurement of RP is useful for the differential diagnoses and analysis of platelet kinetics.
Platelets were identified to have a coarse, punctuated reticulum (reticulated platelets; RP) by using a new methylene blue dye in 1969 (1) . It was suggested that those cells might contain increased amounts of cytoplasmic RNA, reflecting thrombopoiesis in bone marrow. Subsequently, it was reported that platelet nucleic acid could be detected with flow cytometry utilizing thiazole orange as dye (2) . RNA-rich platelets were reported to be readily measured by flow cytometry and to provide information on thrombopoietic activity in thrombocytopenic patients (3) . Analysis of RP was indicated to provide a good indication of the rate of platelet production in bone marrow (4) . In the diagnosis of immune thrombocytopenia, flow cytometric analysis of RP was reported to be better than platelet-associated IgG (5) . Furthermore, a significant difference in reticulated platelet count between normal men and women had been shown using erythrocyte thiazole orange fluorescence in whole blood as an internal standard (6) .
Idiopathic thrombocytopenic purpura (ITP) is caused by an immunologic mechanism of antiplatelet antibodies (7) . In this state, platelet production is normal or increased but platelets are hyper-destroyed in spleen. On the other hand, patients with aplastic anemia have low platelet, leukocyte, and erythrocyte counts in peripheral blood and hypoplastic bone marrow. The flow cytometric analysis of RP is suggested to be a useful method for estimating thrombocytopenia. Recently, the instruments for fully automated measurement of RP (modified R2000 fully automated reticulocyte counter), capable of measuring the RP in the peripheral whole blood immediately, was developed. In healthy volunteers, the RP was 0.48 ± 0.26% in men and 0.48 ± 0.32% in women. No significant difference in the RP values due to gender or age (21-60 years) was observed. Furthermore, the reverse correlation was observed between platelet counts and RP. The RP was high in patients with idiopathic thrombocytopenic purpura (ITP), those with high fibrinogen and fibrin degradation products (FDP), and those with high C-reactive protein (CRP), but low in patients after chemotherapy. The RP was highest in active phase of ITP, and relatively high in the partial remission phase of aplastic anemia. In pa-tients after chemotherapy, the patients had a minimum phase of RP and then a maximum phase of RP before platelet counts increased. RP was significantly high in the maximum phase and significantly low in the minimum phase. The relationships between platelet count and RP were negatively correlated in patients with ITP, high FDP, or high CRP, but were not correlated in patients with aplastic anemia, liver disease, or after chemotherapy. These results show that RP re-In this study, we measured the RP in healthy volunteers, thrombocytopenic patients, and in patients with underlying diseases due to thrombocytopenia to examine the usefulness of the RP count for different diagnosis of thrombocytopenia.
MATERIALS AND METHODS
RPs were examined in 287 healthy volunteers (144 female and 143 male; median age, 32 years old; range, 21-60 years old). RP was also measured in 212 patients with thrombocytopenia and underlying diseases of thrombocytopenia: 58 ITP, 23 aplastic anemia (AA), 7 systemic lupus erythematosus (SLE), 49 liver diseases, 8 leukemic patients after chemotherapy, 22 patients with high FDP (> 10 µg/mL), and 45 patients with high CRP (more than 4 mg/dL). The study protocol was approved by the Human Ethics Review Committees of Mie University School of Medicine. ITP was diagnosed by thrombocytopenia, normal bone marrow with more than normal count of megakaryocytes and no other disease due to thrombocytopenia; active phase, less than 50,000/µL of platelet counts; partial remission (PR), 50,000-120,000/µL of platelet counts with or without treatment; complete remission (CR), more than 120,000/µL of platelet counts without treatment. Aplastic ane-mia was diagnosed by thrombocytopenia, anemia, and leukocytopenia without other disease due to pancytopenia; active phase, less than 50,000/µL of platelet counts; partial remission (PR), 50,000-100,000/µL of platelet counts with or without treatment; complete remission (CR), more than 100,000/µL of platelet counts without treatment.
RP was measured by a previously described method (8) . Briefly, approximately 2 mL of whole blood was collected from healthy volunteers or patients and was anticoagulated with ethylenediamine tetraacetic acid (EDTA)-2K. All blood samples were kept at room temperature until analysis. Counts of RP are reported to be stable during 2-6 hours after collection (9) . Total platelet counts and frequency of RP were determined by the modified R2000 (Sysmex Inc., Kobe, Japan) with special software (9) (10) (11) . For measurements of RP, 10 µL of blood was aspirated by the modified R2000 and automatically mixed with 40 µL of of 2.6% auramine O in 95.9% ethylene glycol solution (Ret-Search dye, Sysmex Inc.) to stain the RNA present in reticulocytes and RP. The samples were then irradiated by an argon laser beam at the wavelength of 488 nm. The resulting fluorescence intensity and forward light scatter were measured with flow cytometry ( Fig. 1) (9) . The frequency of RP was expressed as the percentages of total platelet count. The time required to complete all these measurements was approximately 90 seconds. Creactive protein (CRP) was measured using Nassay TIA CRP-S (Nittobo Company, Tokyo, Japan). Fibrin and fibrinogen degradation products (FDP) were measured using LPIA-FDP (Dia-Iatron Company, Tokyo, Japan). Prothrombin time was measured using a Thromborel S (Dade Behring, Tokyo, Japan).
Statistical Analysis
Results are expressed as mean ± SD. Differences between groups were evaluated by one-way ANOVA and the Bonferroni test. For assessment of correlations, coefficients of correlation were determined by Pearson's correlation coefficient and linear regression analysis. In both cases, a p value less than< 0.05 was considered significant.
RESULTS
Mean value of platelet count was 251.5 ± 50.0 × 10 9 /L in female and 243.6 ± 46.8 × 10 9 /L in male. Mean value of RP was 0.48 ± 0.32% in female and 0.48 ± 0.26% in male, and median of RP was 0.40 (range, 0.07%-2.01%) in female and 0.44 (range, 0.09%-2.00%) in male, respectively; there was no difference of RP between fe-male and male (Fig. 2 ). There was no significant difference in the RP values due to age differences (Fig. 3) . The relationship between platelet count and RP was negatively correlated in healthy volunteers (r= 0.348, p < 0.01) ( Fig. 4) . RP was significantly higher in patients with ITP (p < 0.01), those with high CRP (p < 0.01), those with high FDP (p < 0.01), those with SLE (p < 0.05) and those with liver disease (p < 0.05) than in healthy volunteers (Fig. 5 ). In ITP, RP was highest in active phase and that in CR was similar to normal controls ( Table 1 ). In aplastic anemia, RP was within normal range at CR or active phase, but was significantly increased at PR phase (p < 0.01). RP was high in PR phase of aplastic anemia and in those with SLE. In patients after chemotherapy, there were two phases: minimum and maximum of RP. After chemotherapy, the patients had firstly minimum phase of RP and then had maximum phase of RP before increase of platelet counts. RP was significantly higher in the maximum phase (p < 0.01) and significantly lower in minimum phase (p < 0.05) than in healthy volunteers. The relationship between platelet count and RP was negatively correlated in patients with thrombocytopenia and healthy volunteers (r = 0.404, p < 0.01) (Fig. 6 ). The relationship between platelet count and RP was negatively correlated in patients with ITP (r = 0.489, p < 0.01) ( Fig. 7A ) but were tend to be positively correlated in patients with aplastic anemia (Fig. 7B) . The relationship between platelet count and RP was negatively correlated in patients with high FDP (r = 0.425, p < 0.05) and those with high CRP (r = 0.402, p < 0.01) but not in patients with liver diseases (r = 0.196) and in patients after chemotherapy (Fig.  8 ). However, RP was not significantly correlated with CRP, FDP, or PT ( Table 2) .
DISCUSSION
Thrombocytopenia is a common hematologic abnormality that is caused by hypoproduction, hyperdestruction, and sequestration of platelets. It is difficult to distinguish between hypoplastic and hyperdestructive forms of thrombocytopenia. The presence of normal or increased numbers of megakaryocytes in the bone marrow essentially excludes the diagnosis of hypoplastic thrombocytopenia due to aplastic anemia or amegakaryocytic thrombocytopenia. To date, no simple diagnostic test exists to diagnose hyperdestructive thrombocytopenia such as ITP and thrombotic thrombocytopenic purpura (TTP). Although platelet-associated immunoglobulin G (PAIgG) (5, 12) as anti-platelet antibodies was developed to diagnose ITP, the sensitivity or specificity was low. Recently RP (1, 8, 9) and thrombopoietin (TPO) (13, 14) have been developed to evaluate for thrombocytopenia. RP are reported to be younger platelets that have been newly released into circulation (15) . We found that, in healthy volunteers, RP was approximately 0.48%, with no significant difference between female and male, and among various ages, which was different from the previous report (6) . The relationships between platelet count and RP were negatively correlated in healthy volunteers, suggesting that RP may reflect the platelet generation in normal bone marrow.
In various diseases, RP was significantly high in patients with ITP, in those with high CRP, and in those with high FDP. ITP is an autoimmune disease characterized by increased platelet clearance caused by anti-platelet auto-antibodies (16) . The patients with ITP usually have increased megakaryocytes in the bone marrow, and are considered to have high RP (10,17) and normal TPO levels (14, 18) . In ITP, RP was highest in active phase and reduced similar to normal controls in CR, suggesting that RP may reflect to clinical phase of ITP. Although RP was within normal range in patients with active phase or CR of aplastic anemia, RP was high in PR phase. The increase in RP may reflect to the recovery of platelet production in bone marrow in patients with aplastic anemia. RP was also increased in patients with SLE, those with high FDP, and those with high CRP. SLE also has an autoimmune mechanism for thrombocytopenia such as ITP. In those with high FDP and high CRP, aggregation of platelets may be caused by thrombin or an inflammatory reaction and platelet production may be enhanced. In patients after chemotherapy, the patients had a minimum phase of RP and then had a maximum phase of RP before platelet counts increased. RP was sig- 
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nificantly low in minimum phase and significantly high in maximum phase, suggesting that RP may reflect platelet production in bone marrow after chemotherapy. Measurement of RP may be useful for determining the necessity and/or timing of platelet transfusion in patients with thrombocytopenia after chemotherapy. RPs were negatively correlated in patients with ITP, in patients with high FDP, and in those with high CRP, but were not correlated in patients with aplastic anemia and those after chemotherapy. These results suggest that RP is negatively correlated with platelet count in hyperdestructive thrombocytopenia but not correlated with that in amegakaryocytic thrombocytopenia.
